COMPANY
PIPELINE
R&D
IR
PR
CAREERS
Koo Lee, PhD, CEO of Therapex, "Aiming for TRX-221 to be the best..
[eDaily, Reporter Minjoon Shin] “We will build Therapex into a global innovative drug development company on anti-cance..
Therapex and Pinotbio “partner up” to develop next-generation ADC tech..
[eDaily, Reporter Shin Minjun] Gradient's biotech subsidiary, Therapex, announced on the 30th that it has partnered wit..
Therapex Suggests Best-in-Class Potential for 'TRX-211-399' at AACR An..
│Shows improved selectivity and blood-brain barrier permeability compared to pre-existing competitorsKwangwoo Chun, PhD..
Therapex Launches Attack on Tagrisso-Resistant Lung Cancer with Target..
Approval of an Investigational New Drug application (IND) for the Phase 1/2 study of EGFR-TKI Resistant Non-Small Cell..
Therapex Unveils “Broad Spectrum” Strategy for Fourth-Generation Lung ..
Therapex has entered clinical trials to develop a fourth-generation drug for Epidermal Growth Factor Receptor (EGFR) mu..
Therapex Presents Poster on Anticancer Agent for Non-Small Cell Lung C..
Therapex CEO Koo Lee PhD (left) presenting the follow-up results of the preclinical study of the non-small cell lung ca..
Therapex Presents Preclinical Study Results of Non-Small Cell Lung Can..
Therapex, a subsidiary of Gradient, announced on October 10th that it will participate in the European Society for Med..
FDA Approves Therapex's Targeted Anti-Cancer Agent for Non-Small Cell ..
TRX-221's anti-tumor effect in EGFR C797S mutant non-small cell lung cancer patients to be confirmed in clinical trial..
Therapex's Innovative “Broad-Spectrum” Approach in EGFR-Targeted Antic..
Experienced anticancer drug development team leads clinical trials for broad-spectrum drug candidates targeting variou..
EGFR Lung Cancer Game Changer “Tagrisso”, In Development to Expand Ind..
EGFR Lung Cancer Game Changer "Tagrisso," In Development to Expand Indication to Early-Stage PatientsSource: ..